198 related articles for article (PubMed ID: 17984197)
1. Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan.
Liao Z; Robey RW; Guirouilh-Barbat J; To KK; Polgar O; Bates SE; Pommier Y
Mol Pharmacol; 2008 Feb; 73(2):490-7. PubMed ID: 17984197
[TBL] [Abstract][Full Text] [Related]
2. Activity of a novel camptothecin analogue, homocamptothecin, in camptothecin-resistant cell lines with topoisomerase I alterations.
Urasaki Y; Takebayashi Y; Pommier Y
Cancer Res; 2000 Dec; 60(23):6577-80. PubMed ID: 11118036
[TBL] [Abstract][Full Text] [Related]
3. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.
Jensen NF; Agama K; Roy A; Smith DH; Pfister TD; Rømer MU; Zhang HL; Doroshow JH; Knudsen BR; Stenvang J; Brünner N; Pommier Y
J Exp Clin Cancer Res; 2016 Mar; 35():56. PubMed ID: 27029323
[TBL] [Abstract][Full Text] [Related]
4. ABCG2 mediates differential resistance to SN-38 (7-ethyl-10-hydroxycamptothecin) and homocamptothecins.
Bates SE; Medina-Pérez WY; Kohlhagen G; Antony S; Nadjem T; Robey RW; Pommier Y
J Pharmacol Exp Ther; 2004 Aug; 310(2):836-42. PubMed ID: 15075385
[TBL] [Abstract][Full Text] [Related]
5. Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance.
Antony S; Agama KK; Miao ZH; Takagi K; Wright MH; Robles AI; Varticovski L; Nagarajan M; Morrell A; Cushman M; Pommier Y
Cancer Res; 2007 Nov; 67(21):10397-405. PubMed ID: 17974983
[TBL] [Abstract][Full Text] [Related]
6. Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks.
Bailly C; Lansiaux A; Dassonneville L; Demarquay D; Coulomb H; Huchet M; Lavergne O; Bigg DC
Biochemistry; 1999 Nov; 38(47):15556-63. PubMed ID: 10569939
[TBL] [Abstract][Full Text] [Related]
7. Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells.
Desai SD; Li TK; Rodriguez-Bauman A; Rubin EH; Liu LF
Cancer Res; 2001 Aug; 61(15):5926-32. PubMed ID: 11479235
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study.
Tesauro C; Simonsen AK; Andersen MB; Petersen KW; Kristoffersen EL; Algreen L; Hansen NY; Andersen AB; Jakobsen AK; Stougaard M; Gromov P; Knudsen BR; Gromova I
BMC Cancer; 2019 Nov; 19(1):1158. PubMed ID: 31783818
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
Urasaki Y; Laco GS; Pourquier P; Takebayashi Y; Kohlhagen G; Gioffre C; Zhang H; Chatterjee D; Pantazis P; Pommier Y
Cancer Res; 2001 Mar; 61(5):1964-9. PubMed ID: 11280753
[TBL] [Abstract][Full Text] [Related]
10. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6.
Ishii M; Iwahana M; Mitsui I; Minami M; Imagawa S; Tohgo A; Ejima A
Anticancer Drugs; 2000 Jun; 11(5):353-62. PubMed ID: 10912951
[TBL] [Abstract][Full Text] [Related]
11. Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins.
Taniguchi K; Kohno K; Kawanami K; Wada M; Kanematsu T; Kuwano M
Cancer Res; 1996 May; 56(10):2348-54. PubMed ID: 8625310
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of a deletion mutant of DNA topoisomerase I mRNA in a camptothecin-resistant subline of human colon carcinoma.
Yanase K; Sugimoto Y; Tsukahara S; Oh-Hara T; Andoh T; Tsuruo T
Jpn J Cancer Res; 2000 May; 91(5):551-9. PubMed ID: 10835501
[TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.
Jandu H; Aluzaite K; Fogh L; Thrane SW; Noer JB; Proszek J; Do KN; Hansen SN; Damsgaard B; Nielsen SL; Stougaard M; Knudsen BR; Moreira J; Hamerlik P; Gajjar M; Smid M; Martens J; Foekens J; Pommier Y; Brünner N; Schrohl AS; Stenvang J
BMC Cancer; 2016 Jan; 16():34. PubMed ID: 26801902
[TBL] [Abstract][Full Text] [Related]
14. Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters.
Takagi K; Dexheimer TS; Redon C; Sordet O; Agama K; Lavielle G; Pierré A; Bates SE; Pommier Y
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3229-38. PubMed ID: 18089716
[TBL] [Abstract][Full Text] [Related]
15. New Topoisomerase I mutations are associated with resistance to camptothecin.
Gongora C; Vezzio-Vie N; Tuduri S; Denis V; Causse A; Auzanneau C; Collod-Beroud G; Coquelle A; Pasero P; Pourquier P; Martineau P; Del Rio M
Mol Cancer; 2011 May; 10():64. PubMed ID: 21619602
[TBL] [Abstract][Full Text] [Related]
16. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
Antony S; Jayaraman M; Laco G; Kohlhagen G; Kohn KW; Cushman M; Pommier Y
Cancer Res; 2003 Nov; 63(21):7428-35. PubMed ID: 14612542
[TBL] [Abstract][Full Text] [Related]
17. Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs.
Bailly C
Crit Rev Oncol Hematol; 2003 Jan; 45(1):91-108. PubMed ID: 12482574
[TBL] [Abstract][Full Text] [Related]
18. Three missense mutations of DNA topoisomerase I in highly camptothecin-resistant colon cancer cell sublines.
Arakawa Y; Ozaki K; Okawa Y; Yamada H
Oncol Rep; 2013 Sep; 30(3):1053-8. PubMed ID: 23836376
[TBL] [Abstract][Full Text] [Related]
19. Structural insight of DNA topoisomerases I from camptothecin-producing plants revealed by molecular dynamics simulations.
Sirikantaramas S; Meeprasert A; Rungrotmongkol T; Fuji H; Hoshino T; Sudo H; Yamazaki M; Saito K
Phytochemistry; 2015 May; 113():50-6. PubMed ID: 25733498
[TBL] [Abstract][Full Text] [Related]
20. A novel B-ring modified homocamptothecin, 12-Cl-hCPT, showing antiproliferative and topoisomerase I inhibitory activities superior to SN-38.
Bailly C; Laine W; Baldeyrou B; Demarquay D; Huchet M; Coulomb H; Lanco C; Lavergne O; Bigg DC
Anticancer Drug Des; 2001 Feb; 16(1):27-36. PubMed ID: 11762642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
